Acer Therapeutics Resubmits NDA For ACER-001 For Treatment Of Urea Cycle Disorders
(RTTNews) - Pharmaceutical company Acer Therapeutics Inc. (ACER) announced Monday the resubmission of Acer's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
Acer believes the resubmission addresses in full the items raised by the FDA in the Complete Response Letter (CRL). In June 2022, the FDA issued Acer a CRL stating that satisfactory inspection of its third-party contract packaging manufacturer is required before the ACER-001 NDA may be approved.
Acer notified the FDA in the resubmission that the third-party contract packaging manufacturer is ready for inspection.
Acer expects to be notified by the Agency of its decision to accept or reject the resubmission for review within 14 calendar days of receipt of the NDA resubmission.
If the resubmission is deemed complete by the FDA, a resubmission classification (Class 1 or 2) will be assigned and a new Prescription Drug User Fee Act (PDUFA) target action date will be established of either two or six months from the resubmission date depending on the classification and an inspection of the facility will be requested.
For More Such Health News, visit rttnews.com
Acer Therapeutics, Relief Therapeutics Receive CRL From FDA For ACER-001 For UCDs
Euro Higher Against Majors
TSX Down Marginally In Lackluster Trade
Swiss Market Ends On Firm Note
European Stocks Close Mixed After Cautious Session
U.S. Business Inventories Rise In Line With Estimates In June
U.S. Consumer Sentiment Unexpectedly Deteriorates In August
